# A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

> **NCT01709734** · PHASE2 · TERMINATED · sponsor: **LTN PHARMACEUTICALS, INC.** · enrollment: 126 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** galeterone

## Key facts

- **NCT ID:** NCT01709734
- **Lead sponsor:** LTN PHARMACEUTICALS, INC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 126 (ACTUAL)
- **Why stopped:** Study was terminated prematurely in all investigational study centers upon recommendation from the study's Data Monitoring Committee (DMC).

Study was stopped due to lack of efficacy.
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709734, "A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01709734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*